Blood cancer is a broad term for cancers that affect the production and function of blood cells. Most blood cancers start in the bone marrow, the spongy tissue inside your bones where blood cells are made. In a healthy body, bone marrow produces red blood cells, white blood cells, and platelets in a tightly controlled process. In blood cancer, that process goes wrong: abnormal cells multiply uncontrollably, crowding out healthy cells and interfering with the body’s ability to fight infections, carry oxygen, or control bleeding.
There are three main categories of blood cancer, each originating in a different type of cell. Together, they account for roughly 10% of all new cancer diagnoses in the United States each year.
The Three Main Types
Leukemia begins in the bone marrow when it produces abnormal white blood cells, red blood cells, or platelets that grow out of control. These faulty cells spill into the bloodstream and can be detected on routine blood tests. Leukemia is further divided into acute forms (fast-growing, requiring immediate treatment) and chronic forms (slower-growing, sometimes monitored for years before treatment is needed).
Lymphoma develops from lymphocytes, a type of white blood cell that forms the backbone of your immune system. Rather than originating in the bone marrow itself, lymphomas typically arise in the lymph nodes, spleen, or other lymphatic tissue. The two major subtypes are Hodgkin lymphoma and non-Hodgkin lymphoma, which differ in how the cancer cells look and behave.
Myeloma targets plasma cells, the white blood cells responsible for producing antibodies. When plasma cells become cancerous, they accumulate in the bone marrow and produce abnormal proteins instead of useful antibodies. Because it usually appears in multiple bone marrow sites at once, it’s commonly called multiple myeloma.
How Blood Cancer Develops
Blood cell production is a continuous, high-volume process. Your bone marrow generates billions of new cells every day from a small pool of stem cells. These stem cells normally divide, mature into specialized blood cells, and eventually wear out and get replaced. Blood cancer begins when a stem cell or an early blood cell acquires a genetic mutation that gives it a survival advantage over its normal neighbors.
That advantage is often subtle at first. A mutated stem cell might renew itself slightly more efficiently, or resist the normal signals that tell a cell to stop dividing. Over time, the mutated cell’s descendants outcompete healthy cells, gradually taking over more and more of the bone marrow. Inflammation can accelerate this process: normal stem cells tend to burn out under inflammatory stress, while certain mutated cells are more resilient, allowing them to expand even faster. As the abnormal population grows, it leaves less room for the production of normal red blood cells, white blood cells, and platelets, which is why blood cancer symptoms often reflect shortages in those healthy cells.
Symptoms to Recognize
Blood cancer symptoms are notoriously vague. Many of them overlap with the flu, a lingering virus, or simple fatigue, which is why early blood cancers are easy to dismiss. The most common signs include:
- Persistent fatigue or weakness that doesn’t improve with rest
- Frequent or unusually severe infections
- Unexplained weight loss
- Fever or chills without an obvious cause
- Swollen lymph nodes, particularly in the neck, armpits, or groin
- Easy bruising or bleeding, including recurrent nosebleeds
- Tiny red spots on the skin (called petechiae), caused by broken blood vessels
- Drenching night sweats
- Bone pain or tenderness
No single symptom on this list points definitively to blood cancer. But a combination of several, especially ones that persist for weeks or worsen over time, warrants a blood test to check your cell counts.
How Blood Cancer Is Diagnosed
Diagnosis usually starts with a complete blood count, a simple blood draw that measures the levels of red cells, white cells, and platelets. Abnormal numbers or the presence of immature cells in the blood can raise suspicion, but a blood test alone rarely confirms a diagnosis.
The definitive test is a bone marrow exam. A doctor inserts a thin needle into the back of your hip bone to withdraw a small sample of liquid marrow (aspiration) and a tiny core of bone tissue (biopsy). Both samples are examined under a microscope to determine whether the marrow is producing normal cells or has been overtaken by cancerous ones. The procedure takes about 15 to 30 minutes. Most patients describe it as uncomfortable but tolerable, with pressure and a brief sharp ache when the sample is drawn.
Additional testing on the marrow sample identifies the specific genetic mutations driving the cancer, which directly shapes treatment decisions. Imaging scans may also be used, particularly for lymphoma, to see whether cancer has spread to lymph nodes or organs.
Staging and Classifying the Disease
Blood cancers are staged differently than solid tumors, since they aren’t confined to a single lump that can be measured. Staging systems vary by type. For chronic lymphocytic leukemia, one of the most common blood cancers in adults, doctors use the Rai staging system, which runs from stage 0 through stage IV. Stage 0 means abnormal lymphocyte counts are elevated but lymph nodes, spleen, and liver are normal, and red blood cell and platelet counts remain near normal. By stage IV, platelet counts have dropped significantly and organs may be enlarged. Early stages often require no treatment at all, just regular monitoring.
Lymphomas use a different system based on how many lymph node groups are affected and whether the cancer has crossed the diaphragm or reached organs outside the lymphatic system. Myeloma staging relies on blood markers that reflect how much cancer is present and how much damage it has caused to bones and kidneys.
Treatment Options
Treatment depends heavily on the type, stage, and genetic profile of the cancer. Not all blood cancers require immediate treatment. Chronic forms, particularly early-stage chronic lymphocytic leukemia, are often managed with a “watch and wait” approach: regular blood tests and check-ups every few months, with treatment held off until the disease shows signs of progressing. Some patients remain on watchful waiting for years.
When treatment is needed, options include chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplant. Chemotherapy works by killing rapidly dividing cells, but it can’t distinguish cancer cells from healthy fast-dividing cells, which is why it causes side effects like hair loss, nausea, and increased infection risk. Targeted therapies are more precise, blocking specific proteins that cancer cells rely on to grow. They generally cause fewer side effects than traditional chemotherapy.
One of the most significant advances in recent years is CAR T-cell therapy, a form of immunotherapy that reprograms a patient’s own immune cells to hunt cancer. Doctors collect T cells (a type of immune cell) from the patient’s blood, genetically engineer them in a lab to recognize a specific protein on the cancer cell surface, and then infuse them back into the patient. These modified cells multiply inside the body and attack cancer cells with that protein. For patients with advanced lymphomas that haven’t responded to other treatments, CAR T-cell therapy has transformed the outlook from essentially untreatable to potentially curable. It’s also being used in certain types of leukemia, where it can spare children from years of additional chemotherapy.
Stem Cell Transplants
A stem cell transplant replaces diseased bone marrow with healthy stem cells. In an allogeneic transplant, the stem cells come from a matched donor, often a sibling or unrelated volunteer. In an autologous transplant, a patient’s own stem cells are collected, the patient undergoes intensive treatment to destroy the cancerous marrow, and then the stored stem cells are reinfused to rebuild healthy marrow. Autologous transplants carry lower risk of rejection but lack the immune benefit that donor cells can provide against remaining cancer cells. Both types involve weeks of recovery in a hospital setting and months of immune vulnerability afterward.
Survival and Long-Term Outlook
Survival rates for blood cancers have improved substantially over the past two decades. The five-year relative survival rate for leukemia is now 68.6%, meaning about two out of three patients are alive five years after diagnosis. That number is an average across all leukemia subtypes and ages. Some forms, like acute lymphoblastic leukemia in children, have cure rates above 90%, while others, like acute myeloid leukemia in older adults, remain more difficult to treat.
Hodgkin lymphoma has one of the highest survival rates of any cancer, exceeding 85% at five years. Non-Hodgkin lymphoma and myeloma vary more widely depending on the subtype and how early the disease is caught.
For people living with chronic blood cancers, long-term management often involves periodic blood tests and follow-up exams to track whether the disease is stable, progressing, or returning after treatment. Some of the same tests used at diagnosis are repeated over time to guide decisions about starting, changing, or stopping treatment. Many patients with chronic forms live with their disease for decades, adjusting treatment as needed while maintaining a relatively normal daily life.
Risk Factors
Most blood cancers arise from random genetic mutations that accumulate over a lifetime, which is why the risk increases with age. Certain inherited genetic conditions significantly raise the odds. Down syndrome, for example, increases the risk of childhood leukemia. Inherited syndromes that impair DNA repair, suppress the immune system, or cause bone marrow to fail can also predispose someone to blood cancer, though these conditions are rare.
Environmental factors play a role as well. Prolonged exposure to benzene (found in some industrial chemicals, gasoline, and cigarette smoke) is one of the most well-established environmental risk factors. Previous cancer treatment with certain chemotherapy drugs or radiation therapy can damage bone marrow and increase the risk of developing a secondary blood cancer years later. Smoking, high-dose radiation exposure, and some viral infections (including Epstein-Barr virus and certain retroviruses) are also linked to higher risk. For most people diagnosed with blood cancer, however, no single identifiable cause is found.